What is HC Wainwright’s Forecast for TRVI FY2030 Earnings?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – HC Wainwright dropped their FY2030 earnings per share (EPS) estimates for Trevi Therapeutics in a research report issued to clients and investors on Tuesday, August 11th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of $0.65 for the year, down from their previous forecast of $0.70. HC Wainwright has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.48) per share.

Several other equities analysts have also recently issued reports on the stock. BMO Capital Markets began coverage on shares of Trevi Therapeutics in a research note on Monday, July 20th. They issued an “outperform” rating and a $36.00 target price for the company. B. Riley Financial raised their price target on shares of Trevi Therapeutics from $21.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Oppenheimer lifted their price objective on shares of Trevi Therapeutics from $24.00 to $25.00 and gave the company an “outperform” rating in a report on Friday. Morgan Stanley reaffirmed an “overweight” rating and issued a $23.00 price objective on shares of Trevi Therapeutics in a report on Friday. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $40.00 price objective on shares of Trevi Therapeutics in a research report on Friday. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Trevi Therapeutics currently has an average rating of “Buy” and a consensus price target of $26.75.

Trevi Therapeutics Price Performance

Shares of NASDAQ TRVI opened at $17.80 on Wednesday. The stock has a market capitalization of $2.54 billion, a price-to-earnings ratio of -52.35 and a beta of 1.03. Trevi Therapeutics has a 12 month low of $6.93 and a 12 month high of $20.22. The firm’s 50 day simple moving average is $17.13 and its 200-day simple moving average is $14.13.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11).

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. lifted its position in shares of Trevi Therapeutics by 194.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after buying an additional 2,996 shares in the last quarter. KBC Group NV purchased a new stake in Trevi Therapeutics in the 1st quarter worth $29,000. Hilton Head Capital Partners LLC purchased a new stake in Trevi Therapeutics in the 4th quarter worth $40,000. Caitong International Asset Management Co. Ltd acquired a new position in Trevi Therapeutics during the fourth quarter worth $50,000. Finally, Strs Ohio acquired a new position in Trevi Therapeutics during the first quarter worth $52,000. 95.76% of the stock is owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.